2024 A Focus on Radiation Oncology

ACI: A Focus on Radiation Oncology

Sunday, sept. 29, 2024 | 2:30-4:30 p.m. ET
live at astro 2024 in Washington, dc

Register Now

Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of the clinical implementation of radiation oncology. 

SITC is pleased to present this session in collaboration with the American Society of Radiation Oncology (ASTRO) as part of ASTRO’s 2024 Annual Meeting. 

The 2024 Advances in Cancer Immunotherapy™ series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc.  (MSD), and Novartis Pharmaceuticals Corporation (supporters as of March 22, 2024).

Session Organizers

Sandra Demaria, MD

Sandra Demaria, MD
Weill Cornell Medical College

Zachary Morris, MD, PhD

Zachary Morris, MD, PhD
University of Wisconsin Hospitals and Clinics

Program Snapshot

Credits Available
Physician Education: 2 AMA PRA Category 1TM

Program Date & Location

Sunday, Sept. 29, 2024 at 2:30-4:30 p.m. ET
Live at ASTRO 2024 in Washington, DC

Program Cost

Free with registration to ASTRO 2024.

Register for A Focus on Radiation Oncology >

Session Agenda

2:30–2:35 p.m.

 

Welcome/Introduction
Sandra Demaria, MD – Weill Cornell Medical College

2:35–2:55 p.m.

 

The State of Science
Zachary Morris, MD, PhD – University of Wisconsin Hospitals and Clinics

2:55–3:15 p.m.

   The State of Clinical Practice
Jonathan Schoenfeld, MD – Brigham and Women's Hospital

3:15–3:35 p.m.

 

The State of Clinical Translation
James Welsh, MD – MD Anderson Cancer Center

3:35–3:55 p.m.

 

Advancing Translational Research
Kristina Young, MD, PhD – The Oregon Clinic Radiation Oncology

3:55–4:15 p.m.

 

Clinical Case Discussions
Encouse Golden, MD, PhD – Weill Cornell Medical College

4:15–4:30 p.m.

 

Closing Remarks, SITC Resources
Sandra Demaria, MD – Weill Cornell Medical College

SITC ACI Series

This program is part of the SITC ACI series. View below to explore more programs in the 2024 ACI series.


Session Details

Session highlights

  • Learn the rationale for combining radiation therapy with different types of immunotherapy, as well as the factors that need to be considered as they may affect the efficacy of the treatment, including the radiation dose and field, and sequencing of radiation with immunotherapy.

  • Gain an understanding of the current status of knowledge of the mechanisms of action of combinations of immunotherapeutic agents and radiation that can inform treatment decisions.

  • Examples of specific clinical situations and clinical cases will be discussed.

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Venue Information

Previous Next

Walter E. Washington Convention Center, Washington, DC
801 Allen Y. Lew Place NW Washington, DC 20001 

With a prime location in the heart of downtown, the world-class Walter E. Washington Convention Center is as functional as it is artistically impressive. The 2.3-million-square-foot space hosts meetings, conventions and events of every kind, from medical industry annual meetings to comic book-inspired expos and board retreats.

Accreditation Information 

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

ABIM_Logo.jpg

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physician Continuing Medical Education

PACE designates this live activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Joint Accreditation Statement

thumbnail image In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the Society for Immunotherapy of Cancer (SITC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Disclosure of Conflicts of Interest

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Disclosures